Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68709 | 0.85 | S1PR4 (0.41) | S1PR4TRIM24TRIM33SMN1; SMN2NPC1 | |
| SCHEMBL30020489 | 0.85 | S1PR4 (0.41) | S1PR4TRIM24TRIM33SMN1; SMN2NPC1 | |
| SCHEMBL366056 | 0.82 | S1PR4 (0.41) | S1PR4TRIM24TRIM33SMN1; SMN2NPC1 | |
| SCHEMBL29015868 | 0.78 | MET (0.47) | SMN1; SMN2NPC1RAB9AHTTTRPV4 | |
| SCHEMBL2861434 | 0.77 | MEN1 (0.46) | S1PR4TRIM24TRIM33SMN1; SMN2LMNA | |
| SCHEMBL29099962 | 0.74 | TRPV4 (0.39) | SMN1; SMN2NPC1RAB9ATRPV4LMNA | |
| SCHEMBL25791866 | 0.74 | S1PR4 (0.46) | S1PR4TRIM24TRIM33SMN1; SMN2NPC1 | |
| SCHEMBL28976400 | 0.73 | KDM4E (0.47) | SMN1; SMN2HTTLMNAKDM4E | |
| SCHEMBL10600901 | 0.73 | KMT2A (0.35) | SMN1; SMN2HTT | |
| SCHEMBL1400223 | 0.72 | HTR1A (0.39) | SMN1; SMN2NPC1RAB9AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| EP-1664018-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021529-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | S1PR4 1629/4885TRIM24 3629/4885TRIM33 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.